NKGen Biotech, Inc Common Stock
Yahoo Finance • last year
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease, expect to initiate Phase I/IIa by year end – SNK02 Phase I allogeneic clinical program... Full story
Yahoo Finance • last year
NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (ADCOMS) following 11 weeks SNK01 given intravenously (IV) appears to cross the blood-brain barrier to reduce Cere... Full story
Yahoo Finance • last year
NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
NKGen’s neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by year-end 2023 NKGen’s SNK01 program continues to show positive progress in Alzheimer’s Disease, as demonstrated... Full story
Yahoo Finance • last year
NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
SANTA ANA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogene... Full story
Yahoo Finance • last year
NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
SANTA ANA, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogene... Full story
Yahoo Finance • last year
NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
SANTA ANA, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogene... Full story
